Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

118.28 3.01 −2.48%
Market cap
$5.5B
P/E
57.7×
Fwd P/E
18.0×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
36.59 27.76 21.96 14.17

+8 more quarters

P/S ratio
2.52 1.99 2.84 1.75
P/FCF ratio
11.63 10.16 12.04 8.95
P/Operating CF
65.02 37.48 40.08 20.84
P/B ratio
4.06 3.34 4.11 2.73
Price to Tangible BV
0.00 0.00 0.00 0.00
EV/Sales
3.22 2.72 3.27 2.22
EV/EBITDA
15.88 13.25 11.57 8.01
EV/Operating CF
13.25 12.39 12.71 10.18
EV/FCF
14.86 13.88 13.83 11.36
Quick Ratio
1.67 1.64 1.04 0.92
Current Ratio
3.08 2.95 1.75 1.64
Net Debt/EBITDA
11.18 226.86 5.79 7.03
Debt/Assets
49.43% 50.90% 36.93% 37.69%
Debt/Equity
1.40 1.53 1.01 1.08
Asset Turnover
0.56 0.55 0.53 0.53
Operating CF/Net income
1.59 (3.52) 2.09 2.88
Capex/Depreciation
(0.28) (0.63) (0.21) (0.16)
Interest Coverage
5.81 (4.28) 9.08 8.12
Research and Development Expense of Revenue
4.77% 4.17% 4.19% 4.54%
Selling, General and Administrative Expense of Revenue
35.05% 34.92% 32.20% 31.05%
Intangible Assets out of Total Assets
0.46 0.46 0.41 0.42
Share Based Compensation of Revenue
2.74% 2.64% 2.30% 2.32%
Graham Net Nets
(0.21) (0.29) (0.17) (0.30)
Graham Number
29.18 27.77 40.00 37.16
Earnings Yield
2.73% 3.60% 4.55% 7.06%
Free Cash Flow Yield
8.60% 9.85% 8.30% 11.17%
Revenue per Share
7.48 7.34 7.24 6.88
Operating CF per Share
1.15 1.50 2.00 2.34
Capex per Share
(0.17) (0.36) (0.13) (0.10)
Free Cash Flow per Share
0.98 1.14 1.87 2.24
Cash per Share
4.92 5.20 7.77 6.23
Shareholders Equity per Share
18.45 16.88 19.48 17.84
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
18.45 16.88 19.48 17.84
Free Cash Flow
44.65 53.81 87.65 106.43
Working Capital
547.60 552.28 403.81 351.36
Capital Expenditures
(7.67) (17.13) (5.92) (4.90)
Net Current Asset Value
(717.47) (764.73) (635.76) (693.30)
EV/EBIT
27.12 23.18 17.15 12.13
Capex to Sales
0.02 0.05 0.02 0.02
Price to Operating Income
21.22 16.97 14.94 9.56
Other line items
Average Receivables
208.41 209.76 203.83 210.30
Average Payables
51.17 59.03 55.84 65.47
Average Inventory
333.63 335.76 340.40 359.16
Average Assets
2,413.75 2,423.44 2,511.08 2,483.69
Average Common Equity
859.70 808.58 909.16 864.01

Fold the line items

Columns are period end dates